1. Home
  2. PFX vs VIGL Comparison

PFX vs VIGL Comparison

Compare PFX & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PFX
  • VIGL
  • Stock Information
  • Founded
  • PFX 2010
  • VIGL 2020
  • Country
  • PFX United States
  • VIGL United States
  • Employees
  • PFX N/A
  • VIGL N/A
  • Industry
  • PFX Finance: Consumer Services
  • VIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • PFX Finance
  • VIGL Health Care
  • Exchange
  • PFX Nasdaq
  • VIGL Nasdaq
  • Market Cap
  • PFX 98.8M
  • VIGL 89.3M
  • IPO Year
  • PFX N/A
  • VIGL 2022
  • Fundamental
  • Price
  • PFX $53.20
  • VIGL $3.03
  • Analyst Decision
  • PFX
  • VIGL Strong Buy
  • Analyst Count
  • PFX 0
  • VIGL 5
  • Target Price
  • PFX N/A
  • VIGL $21.00
  • AVG Volume (30 Days)
  • PFX 3.2K
  • VIGL 642.5K
  • Earning Date
  • PFX 02-07-2025
  • VIGL 03-25-2025
  • Dividend Yield
  • PFX 5.15%
  • VIGL N/A
  • EPS Growth
  • PFX N/A
  • VIGL N/A
  • EPS
  • PFX 8.16
  • VIGL N/A
  • Revenue
  • PFX $22,676,403.00
  • VIGL N/A
  • Revenue This Year
  • PFX $16.80
  • VIGL N/A
  • Revenue Next Year
  • PFX $0.74
  • VIGL N/A
  • P/E Ratio
  • PFX $6.52
  • VIGL N/A
  • Revenue Growth
  • PFX 7.21
  • VIGL N/A
  • 52 Week Low
  • PFX $42.50
  • VIGL $1.49
  • 52 Week High
  • PFX $53.50
  • VIGL $6.06
  • Technical
  • Relative Strength Index (RSI)
  • PFX 71.97
  • VIGL 77.87
  • Support Level
  • PFX $47.00
  • VIGL $2.71
  • Resistance Level
  • PFX $53.50
  • VIGL $2.95
  • Average True Range (ATR)
  • PFX 1.02
  • VIGL 0.21
  • MACD
  • PFX 0.50
  • VIGL 0.03
  • Stochastic Oscillator
  • PFX 95.44
  • VIGL 86.18

About PFX PhenixFIN Corporation

PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Share on Social Networks: